Octagam (Human Normal Immunoglobulin)

The IgG antibodies in Octagam bind to a wide range of antigens, supplementing the patient’s own antibody pool. This restores humoral immunity, neutralises pathogens, and modulates immune‑cell signaling through Fc‑receptor pathways, which can dampen autoimmune attacks and improve immune defence.

Dosing is individualized; the prescribing clinician determines the dose, infusion rate, and treatment interval based on the patient’s weight, indication, and clinical response. No standard regimen is provided here.

Human immunoglobulin products are generally considered low risk in pregnancy and lactation because they are not actively transferred in harmful amounts. However, use should only occur when clearly needed and under medical supervision, with benefits weighed against any potential risk.

To request Octagam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Octagam is a 10% liquid IVIG similar to other licensed preparations such as Privigen or Gamunex. All provide pooled IgG, but they differ in manufacturing processes, stabilisers, and osmolarity, which can affect tolerability, infusion rates and specific regulatory approvals in various regions.

Octagam must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original container, protected from light, and must never be frozen or shaken, as this could damage the protein structure.

Octagam is given as an intravenous infusion. The product is diluted according to the manufacturer’s instructions and infused slowly, typically over several hours, with vital signs monitored throughout the procedure to detect any adverse reactions.

Serious adverse events include anaphylaxis, acute renal failure, thromboembolic complications, aseptic meningitis, and severe hypotension. Prompt recognition and medical management are essential if any of these reactions occur during or after infusion.

Octagam is contraindicated in patients with a known severe IgA deficiency who have anti‑IgA antibodies, and in individuals who have experienced a severe hypersensitivity reaction to any immunoglobulin product. Caution is also advised for those with uncontrolled renal or thrombotic disorders.